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Journal of Cystic Fibrosis 13 (2014) 357–358The phenomenal improvement in survival of children and
adults with cystic fibrosis (CF) is one of the unsung success
stories of modern medicine. A lethal disease with no current
cure which previously was considered to be associated with
early death in childhood is now one of adult survival. The two
senior statesman of CF who have written this editorial can well
remember the medical carnage and sustained mortality of
children with CF that occurred in the late 60s and early 70s.
Facilities and therapy for the care of paediatric and adult
patients with CF in Europe were negligible. Gradually this
dismal scenario has been transformed and eroded whereby the
morbidity and almost all of the mortality associated with CF
has shifted to adults. Adults with CF have become older than
members of their healthcare team and survival curves have
improved decade on decade; median survival is now into the
fifth decade of life in parts of the world. This survival success
for CF as a lethal disease far outstrips the survival figures for
many common cancers and other lethal diseases.
How has this success story been achieved? Clearly there have
been significant therapeutic advances which have controlled and
modulated disease progression but most important has been the
recognition that CF is a complex multisystem disease which
requires long term, centralized and multidisciplinary team (MDT)
care with designated facilities. An MDT will consist of many
different disciplines such as physiotherapists, doctors, dieticians,
nurses, social workers and clinical psychologists.
The first step to improve quality is to measure outcomes. The
advent of CF registries has examined outcomes in CF centers for
prime markers which influence disease progression such as lung
function, nutritional status and microbiological prevalence of
infecting (and even cross infecting) organisms. These registries
have illustrated variation between centers within and between
countries [1–3]. Often these variations are understandable and
related to poor funding and resourcing of CF care, however, they
also point to different practices and treatment approaches. Bench
marking comparisons revealed differences in disease severity
of patients between the centers. Further studies revealed that
centers that had better results were characterized by maintaining
standards of care and adherence to guidelines [4–6].
The document Standards of Care of Children and Adults
with Cystic Fibrosis in the UK was updated in 2011 and hashttp://dx.doi.org/10.1016/j.jcf.2014.05.003
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centers in the UK [7]. Published in this special supplement of
the Journal are the updated European Cystic Fibrosis Society
Standards of Care. They undoubtedly break new ground in their
concept. Under the title heading of Standards of Care they are
three separate papers;
1) A Framework for the Cystic Fibrosis Center [8] which
describes the recognised requirements of care in a CF center
2) Best Practice Guidelines [9] which details questions and
answers to the most common clinical problems in CF care
3) Quality Management in Cystic Fibrosis [10] (vide infra).
Each of the monographs is multi-authored by world- wide
experts in CF and is clearly the distillation of considerable hard
work and expertise. Each of the papers is well written and
essential reference material for benchmarking CF care. The best
practice document is an important tool to standardize the daily
care of patients with CF. It provides guidelines many of which
are based on experts' opinions and not on evidence based on
clinical trials. Therefore these guidelines need to be reviewed
regularly and physicians should keep updated with the medical
literature for updates or changes.
However, the paper addressing Quality management in
Cystic Fibrosis is the most interesting. It is essential reading for
all leads of the MDT in CF centers. It describes the process of
evaluating quality care delivered at patient, center and national
level. As a consequence of accumulated data from registries
national and international comparisons can be made for CF
care. The need for patient involvement is emphasized.
The question that needs to be asked is whether these
European Cystic Fibrosis Society Standards of Care have the
power to influence and improve European care of CF children
and adults. The drive to provide high level CF care will be
different for economically advantaged and disadvantaged
countries. There are several steps needed in order to modify
traditional practices and implement changes in the care of
patients. It needs leadership by the CF Center Directors and
their teams since many of these guidelines do not require extra
resources. In addition, these documents should be a road
map for health policy makers to plan the development of theirll rights reserved.
358 Editorialinstitutions or communities care. By standardization of care and
comparison of outcomes through registries it will be possible to
identify areas that need to be augmented in order to improve
outcome. Peer Review has made considerable differences to
improving CF within the UK over the last decade and the
topic of peer review and quality accreditation programmes is
carefully discussed in quality management in cystic fibrosis.
These documents present the current optimal standards of
care; a goal that needs to be adopted by all centers in all the
countries. We suggest that each of the centers will review their
own practice and point the areas that need to be improved.
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